Corrigendum to "In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome" [J. Mol. Cell. Cardiol. (2014) 126-137], DOI: 10.1016/j.yjmcc.2014.02.018;In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome

Journal of Molecular and Cellular Cardiology

Volumn 72, Issue , 2014, Pages 126-137

  Romero, Lucia ^a   Trenor, Beatriz ^a   Yang, Pei Chi ^b   Saiz, Javier ^a   Clancy, Colleen E ^b  

^a UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Computer modeling; Drug induced arrhythmias; Drug induced long QT syndrome; Genetics; Mutations; Potassium channels

Indexed keywords

ACTILIDE; ASTEMIZOLE; CISAPRIDE; DOFETILIDE; INACTILIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL BLOCKING AGENT; SOTALOL; TERFENADINE; UNCLASSIFIED DRUG; ANTIARRHYTHMIC AGENT; KCNE2 PROTEIN, HUMAN; PHENETHYLAMINE DERIVATIVE; SULFONAMIDE; VOLTAGE GATED POTASSIUM CHANNEL;

ACQUIRED LONG QT SYNDROME; ACTION POTENTIAL; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL ACTIVATION; CELL DEACTIVATION; CELL INACTIVATION; CHANNEL GATING; CHINESE HAMSTER; COMBINATION CHEMOTHERAPY; COMPUTER MODEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; FEMALE; GENE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HEART RATE; HERG GENE; HUMAN; HUMAN CELL; KINETICS; LATENT PERIOD; LONG QT SYNDROME; MATHEMATICAL ANALYSIS; MIRP1 GENE; MONOTHERAPY; MUTAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PHASE TRANSITION; PHENOTYPE; POTASSIUM CONDUCTANCE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROTEIN CONFORMATION; PROTEIN FUNCTION; REPOLARIZATION; AGONISTS; CHEMICALLY INDUCED; COMPUTER SIMULATION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HEART VENTRICLE; METABOLISM; MUTATION; PATHOLOGY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ACTION POTENTIALS; ANTI-ARRHYTHMIA AGENTS; ASTEMIZOLE; CISAPRIDE; COMPUTER SIMULATION; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HEART VENTRICLES; HUMANS; ION CHANNEL GATING; KINETICS; LONG QT SYNDROME; MODELS, STATISTICAL; MUTATION; PHENETHYLAMINES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED; PROTEIN CONFORMATION; SEVERITY OF ILLNESS INDEX; SOTALOL; SULFONAMIDES; TERFENADINE;

EID: 84901309212     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.07.022     Document Type: Erratum

References (37)

1. Sesti F., Abbott G.W., Wei J., Murray K.T., Saksena S., Schwartz P.J., et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000, 97:10613-10618.
2. Cubeddu L.X., Iatrogenic Q.T. Abnormalities and fatal arrhythmias: mechanisms and clinical significance. Curr Cardiol Rev 2009, 5:166-176.
3. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003, 58:32-45.
4. Abbott G.W., Sesti F., Splawski I., Buck M.E., Lehmann M.H., Timothy K.W., et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999, 97:175-187.
5. Yang P., Kanki H., Drolet B., Yang T., Wei J., Viswanathan P.C., et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002, 105:1943-1948.
6. + channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995, 92:3381-3386.
7. Rossenbacker T., Priori S.G. Clinical diagnosis of long QT syndrome: back to the caliper. Eur Heart J 2007, 28:527-528.
8. Shimizu W., Noda T., Takaki H., Kurita T., Nagaya N., Satomi K., et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol 2003, 41:633-642.
9. Brugada R., Brugada J., Antzelevitch C., Kirsch G.E., Potenza D., Towbin J.A., et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000, 101:510-515.
10. Fish J.M., Antzelevitch C. Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm 2004, 1:210-217.
11. Kaab S., Hinterseer M., Nabauer M., Steinbeck G. Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome-a case-control pilot study using i.v. sotalol. Eur Heart J 2003, 24:649-657.
12. Jeyaraj D., Abernethy D.P., Natarajan R.N., Dettmer M.M., Dikshteyn M., Meredith D.M., et al. I(Kr) channel blockade to unmask occult congenital long QT syndrome. Heart Rhythm 2008, 5:2-7.
13. + current to repolarization of the human ventricular action potential. Prog Biophys Mol Biol 2008, 96:357-376.
14. O'Hara T., Virag L., Varro A., Rudy Y. Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput Biol 2011, 7:e1002061.
15. Perry M., Sachse F.B., Sanguinetti M.C. Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator. Proc Natl Acad Sci U S A 2007, 104:13827-13832.
16. Pueyo E., Smetana P., Caminal P., de Luna A.B., Malik M., Laguna P. Characterization of QT interval adaptation to RR interval changes and its use as a risk-stratifier of arrhythmic mortality in amiodarone-treated survivors of acute myocardial infarction. IEEE Trans Biomed Eng 2004, 51:1511-1520.
17. Franz M.R., Swerdlow C.D., Liem L.B., Schaefer J. Cycle length dependence of human action potential duration in vivo. Effects of single extrastimuli, sudden sustained rate acceleration and deceleration, and different steady-state frequencies. J Clin Invest 1988, 82:972-979.
18. Lau C.P., Freedman A.R., Fleming S., Malik M., Camm A.J., Ward D.E. Hysteresis of the ventricular paced QT interval in response to abrupt changes in pacing rate. Cardiovasc Res 1988, 22:67-72.
19. Romero L., Pueyo E., Fink M., Rodriguez B. Impact of ionic current variability on human ventricular cellular electrophysiology. Am J Physiol Heart Circ Physiol 2009, 297:H1436-H1445.
20. Pueyo E., Husti Z., Hornyik T., Baczko I., Laguna P., Varro A., et al. Mechanisms of ventricular rate adaptation as a predictor of arrhythmic risk. Am J Physiol Heart Circ Physiol 2010, 298:H1577-H1587.
21. Saiz J., Gomis-Tena J., Monserrat M., Ferrero J.M., Cardona K., Chorro J. Effects of the antiarrhythmic drug dofetilide on transmural dispersion of repolarization in ventriculum. A computer modeling study. IEEE Trans Biomed Eng 2011, 58:43-53.
22. Perrin M.J., Kuchel P.W., Campbell T.J., Vandenberg J.I. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-a-go-go-related gene channels. Mol Pharmacol 2008, 74:1443-1452.
23. Demolis J.L., Funck-Brentano C., Ropers J., Ghadanfar M., Nichols D.J., Jaillon P. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996, 94:1592-1599.
24. Weerapura M., Nattel S., Chartier D., Caballero R., Hebert T.E. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?. J Physiol 2002, 540:15-27.
25. Weerapura M., Hebert T.E., Nattel S. Dofetilide block involves interactions with open and inactivated states of HERG channels. Pflugers Arch 2002, 443:520-531.
26. Ishii K., Nagai M., Takahashi M., Endoh M. Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency. Cardiovasc Res 2003, 57:651-659.
27. + channels. Circ Res 1998, 82:386-395.
28. + conductance. Proc Natl Acad Sci U S A 2009, 106:20075-20080.
29. Hoffmann P., Warner B. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods 2006, 53:87-105.
30. Itoh H., Sakaguchi T., Ding W.G., Watanabe E., Watanabe I., Nishio Y., et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circ Arrhythm Electrophysiol 2009, 2:511-523.
31. Bellocq C., Wilders R., Schott J.J., Louerat-Oriou B., Boisseau P., Le Marec H., et al. A common antitussive drug, clobutinol, precipitates the long QT syndrome 2. Mol Pharmacol 2004, 66:1093-1102.
32. Sun Z., Milos P.M., Thompson J.F., Lloyd D.B., Mank-Seymour A., Richmond J., et al. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes. J Mol Cell Cardiol 2004, 37:1031-1039.
33. Schechter E., Freeman C.C., Lazzara R. Afterdepolarizations as a mechanism for the long QT syndrome: electrophysiologic studies of a case. J Am Coll Cardiol 1984, 3:1556-1561.
34. Moller C., Witchel H. Automated electrophysiology makes the pace for cardiac ion channel safety screening. Front Pharmacol 2011, 2:73.
35. Durdagi S., Duff H.J., Noskov S.Y. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain. J Chem Inf Model 2011, 51:463-474.
36. + channels. Nature 2010, 466:203-208.
37. Balijepalli S.Y., Anderson C.L., Lin E.C., January C.T. Rescue of mutated cardiac ion channels in inherited arrhythmia syndromes. J Cardiovasc Pharmacol 2010, 56:113-122.